Yield10 Bioscience Valuation

YTEN Stock  USD 0.01  0.00  0.00%   
Yield10 Bioscience seems to be undervalued based on Macroaxis valuation methodology. Our model calculates the value of Yield10 Bioscience from examining the company fundamentals such as Shares Outstanding of 692.68 K, operating margin of (7.12) %, and Return On Asset of -1.78 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Yield10 Bioscience's valuation include:
Price Book
11.2322
Enterprise Value
2.1 M
Enterprise Value Ebitda
(0.49)
Price Sales
0.4606
Enterprise Value Revenue
2.5499
Undervalued
Today
0.01
Please note that Yield10 Bioscience's price fluctuation is out of control at this time. Calculation of the real value of Yield10 Bioscience is based on 3 months time horizon. Increasing Yield10 Bioscience's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Yield10 Bioscience is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Yield10 Stock. However, Yield10 Bioscience's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.015 Real  0.0983 Target  2.83 Hype  0.02 Naive  0.0238
The intrinsic value of Yield10 Bioscience's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Yield10 Bioscience's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
0.1
Real Value
50.85
Upside
Estimating the potential upside or downside of Yield10 Bioscience helps investors to forecast how Yield10 stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Yield10 Bioscience more accurately as focusing exclusively on Yield10 Bioscience's fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
0.000.000.00
Details
Hype
Prediction
LowEstimatedHigh
0.000.0250.77
Details
Naive
Forecast
LowNext ValueHigh
0.00050.0290.94
Details
1 Analysts
Consensus
LowTarget PriceHigh
2.582.833.14
Details
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Yield10 Bioscience's intrinsic value based on its ongoing forecasts of Yield10 Bioscience's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Yield10 Bioscience's closest peers.

Yield10 Bioscience Cash

913,140

Yield10 Valuation Trend

Knowing Yield10 Bioscience's actual value is paramount for traders when making sound investment determinations. Using both Yield10 Bioscience's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.

Yield10 Bioscience Total Value Analysis

Yield10 Bioscience is at this time forecasted to have valuation of 2.07 M with market capitalization of 345.46 K, debt of 3.21 M, and cash on hands of 10.16 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Yield10 Bioscience fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
2.07 M
345.46 K
3.21 M
10.16 M

Yield10 Bioscience Investor Information

About 18.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 20.14. Yield10 Bioscience last dividend was issued on the 16th of January 2020. The entity had 1:24 split on the 3rd of May 2024. Based on the measurements of operating efficiency obtained from Yield10 Bioscience's historical financial statements, Yield10 Bioscience may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.

Yield10 Bioscience Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Yield10 Bioscience has an asset utilization ratio of 1.54 percent. This suggests that the Company is making $0.0154 for each dollar of assets. An increasing asset utilization means that Yield10 Bioscience is more efficient with each dollar of assets it utilizes for everyday operations.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Yield10 Bioscience Ownership Allocation

Yield10 Bioscience maintains 17.54 (%) of its outstanding shares held by insiders and 0.03 (%) owned by institutional investors.

Yield10 Bioscience Profitability Analysis

The company reported the previous year's revenue of 60 K. Net Loss for the year was (14.46 M) with loss before overhead, payroll, taxes, and interest of (6.46 M).

About Yield10 Bioscience Valuation

We use absolute and relative valuation methodologies to arrive at the intrinsic value of Yield10 Bioscience. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Yield10 Bioscience based exclusively on its fundamental and basic technical indicators. By analyzing Yield10 Bioscience's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Yield10 Bioscience's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Yield10 Bioscience. We calculate exposure to Yield10 Bioscience's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Yield10 Bioscience's related companies.
Last ReportedProjected for Next Year
Gross Profit-264.5 K-277.7 K
Pretax Profit Margin(277.05)(263.20)
Operating Profit Margin(276.33)(262.51)
Net Loss(277.05)(263.20)
Gross Profit Margin(3.45)(3.62)

Yield10 Bioscience Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding331.1 K
Shares Float537.5 K

Yield10 Bioscience Current Valuation Indicators

Yield10 Bioscience's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Yield10 Bioscience's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Yield10 Bioscience, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Yield10 Bioscience's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Yield10 Bioscience's worth.
When determining whether Yield10 Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Yield10 Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Yield10 Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Yield10 Bioscience Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Yield10 Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
To learn how to invest in Yield10 Stock, please use our How to Invest in Yield10 Bioscience guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Yield10 Bioscience. If investors know Yield10 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Yield10 Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(20.14)
Revenue Per Share
1.472
Quarterly Revenue Growth
4
Return On Assets
(1.78)
Return On Equity
(15.08)
The market value of Yield10 Bioscience is measured differently than its book value, which is the value of Yield10 that is recorded on the company's balance sheet. Investors also form their own opinion of Yield10 Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Yield10 Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Yield10 Bioscience's market value can be influenced by many factors that don't directly affect Yield10 Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Yield10 Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Yield10 Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Yield10 Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.